Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

28,536 total articles

Nintendo Shares Fall 10% as Questions Mount Over Switch 2 Momentum

Nintendo Shares Fall 10% as Questions Mount Over Switch 2 Momentum

Nintendo's stock tumbled 10% after the company reported strong Switch 2 sales over the year-end shopping period but left its full-year earnings and hardware forecasts unchanged. Analysts and investors expressed unease about the console's early momentum and a perceived shortage of major game releases to sustain demand, while rising memory chip price…

U.S. Extends AGOA Through End of 2026, Sets Stage for Future Changes

U.S. Extends AGOA Through End of 2026, Sets Stage for Future Changes

President Donald Trump signed legislation extending the African Growth and Opportunity Act (AGOA) through December 31, 2026, with the extension applied retroactively from September 30, 2025. U.S. Trade Representative Jamieson Greer said his office will work with Congress this year on updates to expand market access for U.S. firms, farmers and ranch…

Mondelez Flags Tepid Outlook as Price Hikes Weigh on Volumes

Mondelez Flags Tepid Outlook as Price Hikes Weigh on Volumes

Mondelez International reported fourth-quarter revenue and adjusted earnings above analysts' expectations, but warned of constrained demand ahead as consumers shift toward value channels following repeated price increases. The company cites elevated cocoa costs, pre-sourced cocoa contracts for 2026 above current market rates, and weakening U.S. con…

Amgen Tops Estimates as Drug Sales Rise and Tax Rate Falls

Amgen Tops Estimates as Drug Sales Rise and Tax Rate Falls

Amgen reported fourth-quarter results that surpassed analyst expectations, driven by higher drug volumes and a lower tax rate. Revenue reached $9.9 billion and adjusted earnings per share beat estimates, while guidance for 2026 sets a revenue midpoint above Street forecasts. Results were mixed at the product level with strong gains for Repatha and …